Patents Examined by Melissa J Perreira
-
Patent number: 12133900Abstract: The present disclosure relates to compounds that are useful as near-infrared fluorescence probes, wherein the compounds include i) a ligand that binds to a target receptor protein, ii) a dye molecule, and iii) a linker molecule that comprises an amino acid or derivative thereof. The disclosure further describes methods and compositions for making and using the compounds, methods incorporating the compounds, and kits incorporating the compounds. The disclosure also relates to compositions for incorporating the compounds as used for the targeted imaging of tumors. Conjugation of the amino acid linking groups increase specificity and detection of the compound. Methods and compositions for use thereof in diagnostic imaging are contemplated.Type: GrantFiled: November 25, 2020Date of Patent: November 5, 2024Assignee: Purdue Research FoundationInventors: Philip Stewart Low, Sumith A. Kularatne, Sakkarapalayam M. Mahalingam
-
Patent number: 12128114Abstract: The invention relates to a new lutetium-177 therapeutic radiopharmaceutical as an inhibitor of prostate-specific membrane antigen (iPSMA), wherein 1,4,7,10-tetraazacyclododecane-N,N?,N?,N??-tetraacetic acid (DOTA) bonded to the heterocyclic molecule hydrazinonicotinamide (HYNIC), generates a rigid chemical structure that minimises the number of conformers and intramolecular hydrogen bonds, thereby producing a favourable spatial orientation of the active site (Lys(Nal)-NH—CO—NH-Glu) in the molecule, for biological recognition by the PSMA protein. The new 177Lu-DOTA-HYNIC-iPSMA radiopharmaceutical accumulates, with high affinity in vivo, in tumours that overexpress the PSMA protein, acting as a radiotherapeutic agent. The purpose of the invention is to provide a new specific radiopharmaceutical (molecular target radiopharmaceutical) for the treatment of tumours with PSMA overexpression.Type: GrantFiled: March 7, 2019Date of Patent: October 29, 2024Assignee: INSTITUTO NACIONAL DE INVESTIGACIONES NUCLEARESInventors: Guillermina Ferro Flores, Blanca Elí Ocampo García, Myrna Alejandra Luna Gutiérrez, Clara Leticia Santos Cuevas, Erika Patricia Azorín Vega, Nallely Patricia Jiménez Mancilla, Tania Hernández Jiménez, Flor de María Ramírez De La Cruz
-
Patent number: 12121828Abstract: A process for the preparation of a carrier-free Ga-68 solution from an irradiated Zn target, systems comprising components used in the process, and compositions comprising Ga-68 prepared by the process. Purification of Ga-68 is carried out by feeding an irradiation target solution comprising Zn-68, Ga-68 and solid target assembly metals into a system comprising three chromatography columns in succession.Type: GrantFiled: October 12, 2020Date of Patent: October 22, 2024Assignee: Telix ARTMS Inc.Inventors: Joel Oscar Olsson Kumlin, Sogol Borjian Borojeni, Daniel Alexander Childs
-
Patent number: 12115233Abstract: Imaging and radiotherapeutics agents targeting fibroblast-activation protein-? (FAP-?) and their use in imaging and treating FAP-? related diseases and disorders are disclosed.Type: GrantFiled: February 23, 2024Date of Patent: October 15, 2024Assignee: The Johns Hopkins UniversityInventors: Xing Yang, Sridhar Nimmagadda, Steven Rowe, Stephanie Slania, Martin G. Pomper
-
Patent number: 12109276Abstract: The design, synthesis, and functionalization of a conjugate including a tumor-targeting near-infrared (NIR) dye and a therapeutic agent and/or a diagnostic agent, whereby the NIR dye can function to target the therapeutic agent and/or diagnostic agent to tumor cells.Type: GrantFiled: March 11, 2020Date of Patent: October 8, 2024Assignee: Lahjavida, LLCInventors: Lyle D. Small, Ruizheng Wang, Shane M. Crippen
-
Patent number: 12090227Abstract: The present disclosure relates to a method to improve the encapsulation efficiency and physicochemical stability of ginsenosides Rg3 and CK nano-emulsion, belonging to the field of functional emulsions. The method to improve the encapsulation efficiency and physicochemical stability of ginsenosides Rg3 and CK nano-emulsion, includes the following steps: (1) WPI, Tween 80 and water were mixed evenly according to the amount ratio of 0.5 g:0.5-0.7 g:50 mL to obtain the aqueous phase; (2) Mixing a saponin extract containing the minor ginsenosides Rg3 and CK with edible oil evenly to obtain the oil phase; (3) Mixing the aqueous phase with the oil phase, carrying out shearing dispersion to obtain coarse emulsion, and then allowing the coarse emulsion to be subjected to microfluidization homogenization to obtain an oil-in-water nano-emulsion containing the minor ginsenosides Rg3 and CK.Type: GrantFiled: December 1, 2023Date of Patent: September 17, 2024Assignees: JIANGNAN UNIVERSITY, STANDARD FOODS (CHINA) CO., LTD, LE BONTA WELLNESS CO., LTDInventors: Peng Zhou, Changshu Liu, Yaowei Liu, Tao Yang, Yan Zheng, Jianguo Liu, Kexin Li, Shuyan Lu
-
Patent number: 12076443Abstract: A preparation method of a nanozyme composite-based hybrid hydrogel eye drop includes synthesizing a tannin-coordinated silver/cobalt composite nanoparticle through a coordination reaction of cobalt chloride hexahydrate with ammonia water and an oxidation-reduction reaction of silver nitrate with tannin; and mixing the silver/cobalt composite nanoparticle with an acrylate-modified gelatin, conducting an ultrasonic treatment to allow complete dissolution, and irradiating a resulting mixture under ultraviolet (UV) light to obtain the nanozyme composite-based hybrid hydrogel eye drop. The preparation method of the present disclosure has simple operations and a short preparation time. The eye drop prepared by the preparation method shows a broad-spectrum bactericidal effect against a variety of bacteria and fungi, and has prominent preventive and therapeutic effects for bacterial and drug-resistant bacterial corneal infections.Type: GrantFiled: February 15, 2023Date of Patent: September 3, 2024Assignee: INSTITUTE OF OPHTHALMOLOGY AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY (SHANDONG INSTITUTE OF OPHTHALMOLOGY, QINGDAO EYE HOSPITAL AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY)Inventors: Qingjun Zhou, Weiyun Shi, Hongwei Wang, Fangying Song
-
Patent number: 12077741Abstract: The present invention discloses crosslinked poly(alkylene glycol) (PAG)-based hydrogel compositions, systems containing a plurality of cancer cells in contact with a cell culture media and encapsulated in the crosslinked PAG-based hydrogel composition and methods of making such crosslinked hydrogel compositions and systems. Also disclosed herein are methods of using such compositions and systems, such as, for example for screening an agent for effectiveness of the agent against cancer cells. Also disclosed herein are kits containing one or more components including one or more systems of the present disclosure and one or more instructions.Type: GrantFiled: June 4, 2020Date of Patent: September 3, 2024Assignee: University Of DelawareInventors: John H. Slater, Shantanu Pradhan, Cindy Jazmin Farino Reyes
-
Patent number: 12065413Abstract: Compositions and methods for visualizing tissue under illumination with near-infrared radiation, including compounds comprising near-infrared, closed chain, sulfo-cyanine dyes and prostate specific membrane antigen ligands are disclosed.Type: GrantFiled: May 26, 2021Date of Patent: August 20, 2024Assignee: THE JOHNS HOPKINS UNIVERSTYInventors: Martin G. Pomper, Ronnie C. Mease, Ying Chen, Sangeeta Ray
-
Patent number: 12059482Abstract: Activity-based probe compounds for use in labeling a cysteine protease are provided. The compounds are targeted to the protease through a specific targeting element. The compounds additionally include a detectable element, such as a fluorescent label, a radiolabel, or a chelator. In some cases, the compounds additionally include a quenching element that is released upon reaction with the protease. Also provided are compositions comprising the compounds and methods for using the compounds, for example in labeling a protease in an animal and in visualizing a tumor in an animal.Type: GrantFiled: December 18, 2020Date of Patent: August 13, 2024Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Matthew S. Bogyo, Martijn Verdoes
-
Patent number: 12053532Abstract: The present disclosure relates to compounds that are useful as near-infrared fluorescence probes, wherein the compounds include i) a pteroyl ligand that binds to a target receptor protein, ii) a dye molecule, and iii) a linker molecule that comprises an amino acid or derivative thereof. The disclosure further describes methods and compositions for incorporating the compounds as used for the targeted imaging of tumors. Conjugation of the amino acid linking groups increase specificity and detection of the compound. Methods and compositions for use thereof in diagnostic imaging are contemplated.Type: GrantFiled: December 7, 2020Date of Patent: August 6, 2024Assignee: Purdue Research FoundationInventors: Sumith A. Kularatne, Sakkarapalayam M. Mahalingam, Philip S. Low, Mohammad Noshi
-
Patent number: 12048753Abstract: Provided herein are methods for producing site specific PEG modifications to single domain antibodies (e.g., VHHs). Methods for producing site-specifically conjugated bivalent single domain antibodies (e.g., VHHs) are also provided. Methods for labeling (e.g., with a fluorophore or radionuclide) site-specifically PEGylated single domain antibodies and site-specifically conjugated bivalent single domain antibodies are also provided.Type: GrantFiled: October 1, 2016Date of Patent: July 30, 2024Assignee: Whitehead Institute for Biomedical ResearchInventors: Mohammad Rashidian, Hidde L. Ploegh
-
Patent number: 12036289Abstract: The present invention relates to the RRR/SSS pair of enantiomers of the of Gd(PCTA-tris-glutaric acid), the single enantiomers of the pair, the pharmaceutically acceptable salts thereof, their amide derivatives, and compositions comprising at least 50% of these compounds.Type: GrantFiled: March 11, 2021Date of Patent: July 16, 2024Assignee: BRACCO IMAGING S.P.A.Inventors: Roberta Napolitano, Luciano Lattuada, Zsolt Baranyai, Nicole Guidolin, Giuseppe Marazzi
-
Patent number: 11992537Abstract: A compound is provided comprising a melanocortin 1 receptor (MC1R) targeting peptide (MC1RTP), a radiolabeling group, and a linker joining the MC1RTP to the radiolabeling group. The MC1RTP is linear or cyclized, and comprises a sequence of Formula I or Formula II: Xaa1-Xaa2a-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7a (I) or Xaa1-Xaa2b-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7b (II). Xaa1 is L-/D-Nle, L-/D-Nle, L-/D-Ala, L-/D-Leu, L-/D-Ile, D-Ile, L-/D-Cys, L-/D-Met, L-/D-Phe, L-/D-Trp, L-/D-Val, L-/D-Nal, L-/D-2-Nal, Gly, L-/D-?-aminobutryic acid, L-/D-norvaline, or L-/D-homonorleucine. Xaa2a and Xaa7b are L-/D-Cys, L-/D-Asp, L-/D-Glu, L-/D-2-Aad, L-/D-3-Aad, L-/D-Pra, L-/D-Hpg, or L-/D-Bpg. Xaa2b and Xaa7a are L-/D-Cys, L-/D-Lys, L-/D-Orn, L-/D-Dab, L-/D-Dap, L-/D-Lys(N3), L-/D-Orn(N3), L-/D-Dab(N3), L-/D-Dap(N3), L-/D-2-(5?-azidopentyl)alanine, or L-/D-2-(6?-azidohexyl)alanine. Xaa3 is L-/D-His, Pro, beta-(1,2,3-triazol-4-yl)-L-alanine, beta-(1,2,3-triazol-4-yl)-D-alanine, 1,2,4-triazole-3-alanine, or 1,2,4-triazole-3-D-alanine.Type: GrantFiled: May 23, 2019Date of Patent: May 28, 2024Assignee: PROVINCIAL HEALTH SERVICES AUTHORITYInventors: François Bénard, Kuo-Shyan Lin, Chengcheng Zhang, Zhengxing Zhang
-
Patent number: 11992536Abstract: The present disclosure relates to the fields of nuclear medicine and molecular imaging, and specifically relates to a dual-targeting compound and a preparation method and application thereof. The dual-targeting compound has the following structure shown in Formula (I). The present disclosure also provides a dual-targeting compound capable of being labeled with a radionuclide, and the compound has the following structure shown in Formula (I-1) or Formula (1-2). The dual-targeting compound of the present disclosure has high affinity for an FAP target and an integrin ?v?3 target, can realize synergistic targeting of the FAP target and the integrin ?v?3 target in tumors, and has high uptake in tumors and long retention time in tumors.Type: GrantFiled: December 9, 2022Date of Patent: May 28, 2024Assignee: YANTAI LANNACHENG BIOTECHNOLOGY CO., LTD.Inventors: Xiaoyuan Chen, Pengfei Xu, Xiaoming Wu, Zhide Guo, Qingbao Yang, Xuejun Wen
-
Patent number: 11986540Abstract: A composition is configured to be administered to a subject undergoing a malignant lesion resection procedure. The composition comprises a pharmaceutically effective amount of pafolacianine or a pharmaceutically acceptable salt thereof. The pafolacianine or a pharmaceutically acceptable salt thereof is configured to bind one or more malignant lesions and emit an optical signal.Type: GrantFiled: February 20, 2023Date of Patent: May 21, 2024Assignee: ON TARGET LABORATORIES, LLCInventor: Sumith A. Kularatne
-
Patent number: 11975079Abstract: The present disclosure provides a truncated Evans Blue modified fibroblast activation protein inhibitor compound. The compound is formed by connecting truncated Evans Blue, a fibroblast activation protein inhibitor and a nuclide chelating group by means of connecting groups L1, L2, L3, L4 and X. The compound has the following structure shown in Formula (I), where R1 is a fibroblast activation protein inhibitor; L1 is lysine, glutamic acid, or a derivative structure thereof; L2 is —(CH2)n—, n is an integer from 0 to 30, and each —CH2— may be individually substituted or unsubstituted with —O—, —NH—, —(CO)—, —NH(CO)—, or —(CO)—NH—; L3 is —(CH2)m—, m is an integer from 0 to 30, and each —CH2— may be individually substituted or unsubstituted with —O— or —(CO)—; L4 is —(CH2)p—, p is an integer from 0 to 30, and each —CH2— may be individually substituted or unsubstituted with —O—, —NH—, —(CO)—, —NH(CO)—, or —(CO)—NH—; X is selected from N, C, O, S, or and R2 is a nuclide chelating group.Type: GrantFiled: July 11, 2021Date of Patent: May 7, 2024Assignee: YANTAI LANNACHENG BIOTECHNOLOGY CO., LTD.Inventors: Xiaoyuan Chen, Pengfei Xu, Zhide Guo, Xiaoming Wu, Qingbao Yang, Tian He
-
Patent number: 11957766Abstract: The present invention includes a probe, an assay, a method of detecting, a human NAD(P)H quinone oxidoreductase-1 (hNQO1) enzyme activity with a fluorescent probe comprising a quinone propionic acid (QPA) conjugated to dicyanoisophorone (DCP), wherein the hNQO1 reduces the probe to releases a fluorescent DCP, and a method of making the same.Type: GrantFiled: November 17, 2020Date of Patent: April 16, 2024Assignee: TEXAS TECH UNIVERSITY SYSTEMInventors: Kalkunte S. Srivenugopal, Surendra R. Punganuru
-
Patent number: 11951189Abstract: The present invention is directed to sarcophagine based compounds of formula (I). The compounds can complex a radioisotope, such as 64-copper and hence are useful in radioimaging and radiotherapy of cancers, e.g. colorectal cancer. The compounds work via a pre-targeting imaging approach in which the tetrazine reacts via click chemistry with a functional group such as a transcyclooctene which is pre-bound to a ligand such as a tumour specific antibody.Type: GrantFiled: April 11, 2019Date of Patent: April 9, 2024Assignee: Clarity Pharmaceuticals LtdInventors: Paul Stephen Donnelly, Nicholas Alan Zia
-
Patent number: 11945769Abstract: The present invention relates to an N,N?-diurea derivative represented by the following general formula (1) and a method for producing the same. In addition, the present invention relates to a thermosensitive recording material in which a thermosensitive recording layer including a basic dye which is colorless or lightly colored at room temperature and a developer capable of developing color upon contact with the basic dye by heating is provided on a base sheet, wherein the developer is the N,N?-diurea derivative represented by the following general formula (1): (wherein R2 is an alkyl group, an aralkyl group, or an aryl group; and A1 is a hydrogen atom or an alkyl group).Type: GrantFiled: August 10, 2018Date of Patent: April 2, 2024Assignee: SANKO CO., LTD.Inventors: Ryoichi Kinishi, Yoshimi Ishibashi